Thyme Care, the nationally recognized oncology company, today announced a new Series E financing round of over $125M. Morgan Health led the round, with participation from strategic healthcare investors Humana and CVS Health Ventures, as well as institutional investors AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health.